Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

502

Figures (1-3)

Tables (1-1)

Sum=622

Publishing Process of This Article

Item

Count

Browse

Download

Sum=61

May 15, 2024 (publication date) through Jul 2, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Diabetes. May 15, 2024; 15(5): 1011-1020
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.1011

Full Size Figure Download Figure

Figure 2 Risk of overall infections for dipeptidyl peptidase-4 inhibitors treatment vs control. DPP-4: Dipeptidyl peptidase-4.

Citation: Yang N, He LY, Liu P, Li ZY, Yang YC, Ping F, Xu LL, Li W, Zhang HB, Li YX. Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials. World J Diabetes 2024; 15(5): 1011-1020
URL: https://www.wjgnet.com/1948-9358/full/v15/i5/1011.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i5.1011